Mar 14, 2023 / 08:05PM GMT
Peter Richard Lawson - Barclays Bank PLC, Research Division - Research Analyst
So good afternoon, everybody, and welcome to Barclays Healthcare Conference in Miami. Do raise a hand or ping myself or one of my associates if you have questions that need to be addressed. My name is Peter Lawson. I'm one of the biotech analysts at Barclays. I cover mid-cap oncology biotech companies. Really delighted to have up on the stage with me, Sean McCarthy from CytomX.
Questions and Answers:
Peter Richard Lawson - Barclays Bank PLC, Research Division - Research AnalystAnd first question really is kind of the -- I guess the differentiating factor that we have around your approach, kind of, how is that resonating in the sense of partnerships and how partners are perceiving that activation of kind of a prodrug antibody?
Sean A. McCarthy - CytomX Therapeutics, Inc. - Chairman & CEO
Yes. Thanks, Peter, and pleasure to be here. Thanks for the invitation. So just to briefly recap the core technology that we've been developing
Trustpilot
